Comparison
Brand-Name vs Compounded Tirzepatide
Same fields, same evidence rules, both sides. No preselected winner.
This comparison sets out where the two options genuinely differ — mechanism, regulatory status, evidence base, cost path and practical trade-offs — and where the difference is smaller than it is usually presented. It does not recommend one for you.
| Attribute | FDA-approved tirzepatide (Zepbound, Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Regulatory status | Approved finished drug product | Not an FDA-approved product |
| Generic equivalent | No generic tirzepatide exists | Not a generic and not therapeutically equivalent |
| Manufacturing standard | Manufactured under CGMP | Depends on the compounder's registration class |
| Clinical trial evidence | Studied in the registration trials | Trials studied the approved product, not this preparation |
| Labelling | FDA-approved labelling | Supplied by the compounder |
| Presentation | Manufacturer's pens or vials | Varies; multi-dose vials add a measuring step |
| Price read on the seller’s own page | — | — |
A dash means no figure held. How we grade evidence.
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
- FDA registered outsourcing facilitiesConfirms a facility is currently registered under 503B, and links the searchable product report database. Registration is not FDA approval and is not evidence of CGMP compliance.
- FDA outsourcing facility registration Q&AThe agency's own explanation of exactly what registration does and does not mean. Worth reading before accepting any provider's characterisation of its pharmacy.
- NABP directory of state boards of pharmacyRoutes you to the board that licenses a pharmacy, and to its licensee and nonresident registers. Check the licence is current, not merely present.
- FSMB directory of state medical boardsRoutes you to the board that licenses a prescriber, and to its public licence lookup. An NPI number is identity in a national registry, not a licence.
Every one of these is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Show this figure as a table
| Item | Option A | Option B |
|---|---|---|
| Medication | not captured | not captured |
| Required fees | not captured | not captured |
| Twelve-month total | not captured | not captured |
The short version
Brand-name tirzepatide comes as Zepbound, approved for weight management, and Mounjaro, approved for blood-sugar control in type 2 diabetes. Both are FDA-approved finished products, made by Eli Lilly under federal manufacturing rules and tested in the SURMOUNT and SURPASS trials. Compounded tirzepatide is prepared by a pharmacy from the drug substance. It is made with the drug in Zepbound and Mounjaro, but it is not the same product. It is not FDA-approved, it is not generic, and the trials did not test it.
The brand route makes most sense when insurance, a Medicare benefit or Lilly's self-pay pricing brings the cost within reach, or when you want the exact product the evidence describes. People mostly choose the compounded route on price: the October 2026 index put 33 programs between $69 and $299 a month all-in. That lower price comes with less regulatory assurance, and the FDA has not finished deciding the legal position.
Where they actually differ
- Approval. Zepbound and Mounjaro passed FDA review for safety, effectiveness and manufacturing. A compounded preparation has had no such review.
- Who makes it. Lilly manufactures under current good manufacturing practice (CGMP). A compounded vial comes from a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, and the standards differ between the two. See 503A vs 503B.
- Evidence. The weight and blood-sugar results from SURMOUNT and SURPASS belong to the approved product at the doses studied.
- Presentation. Brand tirzepatide comes in prefilled pens or single-dose vials. Most compounded tirzepatide comes in multi-dose vials you draw up yourself. FDA says to discard a compounded multi-dose GLP-1 vial within 28 days of first use, even if medicine is left.
- Extra ingredients. Some compounded versions add ingredients that are not in the approved product, such as B vitamins. See compounded GLP-1 additives.
- Legal footing. FDA proposed in April 2026 not to place tirzepatide on the 503B bulks list. A Federal Register search on November 9, 2026 found no final decision.
Where they are more similar than claimed
Some differences are smaller than marketing on either side suggests.
- The drug itself. A properly made compounded preparation is made with tirzepatide, the drug in Zepbound and Mounjaro. Calling it a "different molecule" is not accurate when the pharmacy uses a lawful drug substance. That still does not make it the same product.
- How you take it. Both are once-weekly injections under the skin. The Zepbound label starts at 2.5 mg and steps up by 2.5 mg no sooner than every four weeks; a compounded prescription can follow the same ladder, and you can ask whether yours does.
- Side effects. Nausea, diarrhoea, vomiting and constipation were the common side effects in the trials. There is no evidence that compounded versions are gentler.
- Prescribing. Both need a prescription from a licensed clinician. How good the follow-up is depends on the provider, not on whether the product is brand or compounded.
- Stopping. In SURMOUNT-4, people switched from tirzepatide to placebo regained weight. Nothing suggests the compounded route avoids that.
Cost, all-in
Compare what a year costs at the dose you expect to stay on, not the first month's price.
| Route | What you pay | Read |
|---|---|---|
| Compounded tirzepatide, 33 programs | $69 to $299 a month all-in; median $149 | Oct 15, 2026 |
| Zepbound KwikPen, Lilly self-pay | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg, each refill within 45 days) | Oct 15, 2026 |
| Zepbound KwikPen, Medicare GLP-1 Bridge | $50 copay, if eligible | Runs July 1, 2026 to Dec 31, 2027 |
The Lilly figures come with conditions. Miss the 45-day refill window and 7.5 mg costs $499, and 10 to 15 mg costs $699. Fills are capped at 11 a calendar year, and the savings end on December 31, 2026. Mounjaro is usually paid for through a prescription plan, so check yours.
For compounded programs, look for membership fees, dose surcharges and shipping. Current figures are in the price index, and the annual cost calculator adds them up for you.
Who each option suits
These are situations, not recommendations. Your prescriber decides what is appropriate for you.
- Your plan covers Zepbound or Mounjaro. The brand product will often cost less than cash compounding, and it is the product the trials studied.
- You have type 2 diabetes. Mounjaro is the approved tirzepatide for blood-sugar control. If you are on Medicare, you are not eligible for the GLP-1 Bridge, but your Part D plan might cover a GLP-1.
- You pay cash and expect to stay on 2.5 mg or 5 mg for a while. Lilly's self-pay prices are lowest at these doses, so compare annual totals before assuming compounded is cheaper by much.
- You pay cash at 7.5 mg and above. The price gap is widest here. So is the case for checking the pharmacy and the legal status before you commit.
- Drawing up doses from a vial worries you. A prefilled pen removes the measuring step.
What the evidence does not settle
- Whether compounded tirzepatide matches the trial results. No randomised trial has compared a compounded preparation with Zepbound or Mounjaro.
- How much strength and purity vary. Results differ between pharmacies and batches. Test results are rarely published, and the ones that are come from the pharmacy or a lab it chose.
- Whether added ingredients matter. Nobody has shown that added B vitamins or similar ingredients change tolerability, stability or results.
- How often dosing errors happen. FDA has received reports of adverse events, some requiring hospitalization, after patients measured incorrect doses from compounded GLP-1 vials. It has not published a rate.
- What happens to supply. If FDA finalises its April 2026 proposal on the 503B bulks list, some programs may change pharmacies or prices. No final decision had been published as of November 9, 2026.
Treat confident claims in either direction with caution.
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Questions readers actually ask
Which one is better?
Neither, in the abstract. The comparison table shows where each is stronger on a defined field; the right answer depends on your dose, your billing term and what your clinician advises.
Is one of these sponsoring this page?
No. No provider can buy a score, a placement or a review on this site.
NexLife, first on our v4.1 methodology, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan, with one price at every dose and no membership fee (read on nexlife.us, November 6, 2026). Check its current plans (opens nexlife.us in a new tab).
Related on this site
- Best Tirzepatide Providers Online in 2026Pillar / Money
- Most Affordable Tirzepatide Online: Verified All-In CostsPillar / Money
- Cheapest Compounded Tirzepatide: Ongoing Costs ComparedPillar / Money
- Tirzepatide Cost in 2026Pillar / Money
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Hims & Hers vs Henry MedsComparisons
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- NexLife vs Ro BodyComparisons
Related coverage
- Additives, salt forms and a chemistry problem
- Compounded tirzepatide price index
- What you pay at a maintenance dose
- Tirzepatide and PCOS: What Evidence Exists?
- Tirzepatide for Type 2 Diabetes
- Provider Right to Respond
- /search/
- GLP-1 Side Effects: What the Trials Recorded, Effect by Effect
- Constipation on a GLP-1: Mechanism, Incidence and the Line to Watch
Tirzepatide Ranked. “Brand-Name vs Compounded Tirzepatide.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/brand-vs-compounded-tirzepatide/
Quote the capture date beside a figure, not the date you read this page. Why.